Concepts (110)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mutation | 3 | 2024 | 817 | 0.360 |
Why?
|
| Diabetic Retinopathy | 5 | 2022 | 108 | 0.320 |
Why?
|
| Retinal Neovascularization | 2 | 2007 | 20 | 0.240 |
Why?
|
| Retinal Diseases | 1 | 2024 | 45 | 0.230 |
Why?
|
| Eye Proteins | 3 | 2020 | 197 | 0.220 |
Why?
|
| Macular Edema | 1 | 2022 | 3 | 0.210 |
Why?
|
| Indians, North American | 6 | 2011 | 511 | 0.200 |
Why?
|
| Punctal Plugs | 1 | 2021 | 3 | 0.190 |
Why?
|
| Dry Eye Syndromes | 1 | 2021 | 5 | 0.190 |
Why?
|
| Retinitis Pigmentosa | 1 | 2020 | 28 | 0.180 |
Why?
|
| Choroidal Neovascularization | 1 | 2000 | 11 | 0.170 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2020 | 54 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 207 | 0.170 |
Why?
|
| Anemia, Sickle Cell | 1 | 2000 | 38 | 0.170 |
Why?
|
| Phenotype | 1 | 2020 | 665 | 0.150 |
Why?
|
| Retina | 4 | 2022 | 422 | 0.150 |
Why?
|
| Fundus Oculi | 4 | 2002 | 15 | 0.130 |
Why?
|
| Retinal Vessels | 3 | 2022 | 71 | 0.130 |
Why?
|
| Fluorescein Angiography | 3 | 2022 | 16 | 0.110 |
Why?
|
| Middle Aged | 10 | 2024 | 6818 | 0.110 |
Why?
|
| Retinal Degeneration | 2 | 2002 | 142 | 0.110 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2005 | 57 | 0.100 |
Why?
|
| Visual Acuity | 3 | 2020 | 106 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2024 | 1091 | 0.100 |
Why?
|
| Child | 4 | 2024 | 2147 | 0.090 |
Why?
|
| Macular Degeneration | 1 | 2011 | 79 | 0.090 |
Why?
|
| Photography | 4 | 2022 | 19 | 0.080 |
Why?
|
| Humans | 13 | 2024 | 26829 | 0.080 |
Why?
|
| Adolescent | 4 | 2024 | 2957 | 0.080 |
Why?
|
| Female | 10 | 2024 | 14463 | 0.080 |
Why?
|
| Pedigree | 3 | 2020 | 153 | 0.070 |
Why?
|
| Macula Lutea | 1 | 1987 | 5 | 0.070 |
Why?
|
| Genes, Dominant | 1 | 1987 | 35 | 0.070 |
Why?
|
| Receptors, LDL | 1 | 2007 | 28 | 0.070 |
Why?
|
| Male | 9 | 2024 | 12870 | 0.070 |
Why?
|
| Neovascularization, Pathologic | 1 | 1987 | 144 | 0.070 |
Why?
|
| Visually Impaired Persons | 1 | 2005 | 5 | 0.060 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2005 | 246 | 0.060 |
Why?
|
| Eye Diseases | 1 | 2005 | 31 | 0.060 |
Why?
|
| Young Adult | 2 | 2024 | 2581 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2005 | 38 | 0.060 |
Why?
|
| Oklahoma | 6 | 2011 | 973 | 0.060 |
Why?
|
| Adult | 4 | 2024 | 7383 | 0.060 |
Why?
|
| Genetic Testing | 1 | 2024 | 64 | 0.060 |
Why?
|
| Tomography, Optical Coherence | 1 | 2024 | 89 | 0.060 |
Why?
|
| Aged | 4 | 2024 | 5167 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2002 | 3 | 0.050 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 1394 | 0.050 |
Why?
|
| Tears | 1 | 2021 | 10 | 0.050 |
Why?
|
| Povidone-Iodine | 1 | 2021 | 8 | 0.050 |
Why?
|
| Intravitreal Injections | 1 | 2021 | 33 | 0.050 |
Why?
|
| Eye | 1 | 2021 | 35 | 0.050 |
Why?
|
| Ophthalmology | 1 | 2001 | 36 | 0.050 |
Why?
|
| Laser Coagulation | 1 | 2000 | 13 | 0.040 |
Why?
|
| Hypertension | 2 | 2011 | 304 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2011 | 1927 | 0.040 |
Why?
|
| Prevalence | 2 | 2011 | 472 | 0.030 |
Why?
|
| Visual Field Tests | 2 | 2002 | 13 | 0.030 |
Why?
|
| Reproducibility of Results | 3 | 2005 | 747 | 0.030 |
Why?
|
| Ophthalmoscopy | 1 | 1993 | 5 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 1993 | 322 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2005 | 472 | 0.020 |
Why?
|
| Sunlight | 1 | 2011 | 10 | 0.020 |
Why?
|
| Vitamins | 1 | 2011 | 22 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2011 | 58 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 64 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 397 | 0.020 |
Why?
|
| Sex Factors | 1 | 2011 | 446 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 162 | 0.020 |
Why?
|
| Risk Factors | 2 | 2011 | 2011 | 0.020 |
Why?
|
| Age Factors | 1 | 2011 | 716 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 858 | 0.020 |
Why?
|
| Vision, Ocular | 1 | 1987 | 27 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2007 | 16 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2007 | 21 | 0.020 |
Why?
|
| Electrophysiology | 1 | 1987 | 150 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 50 | 0.020 |
Why?
|
| Nerve Growth Factors | 1 | 2007 | 24 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 57 | 0.020 |
Why?
|
| Serpins | 1 | 2007 | 31 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 83 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 324 | 0.020 |
Why?
|
| NF-kappa B | 1 | 2007 | 187 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2001 | 508 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 147 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 176 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2007 | 453 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2007 | 560 | 0.020 |
Why?
|
| Exudates and Transudates | 1 | 2005 | 11 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2007 | 503 | 0.020 |
Why?
|
| Retinal Hemorrhage | 1 | 2005 | 7 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2005 | 30 | 0.020 |
Why?
|
| Aneurysm | 1 | 2005 | 25 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2007 | 783 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2005 | 910 | 0.010 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2002 | 6 | 0.010 |
Why?
|
| Dark Adaptation | 1 | 2002 | 11 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 262 | 0.010 |
Why?
|
| Electroretinography | 1 | 2002 | 173 | 0.010 |
Why?
|
| Mice | 1 | 2007 | 4408 | 0.010 |
Why?
|
| Animals | 1 | 2007 | 9963 | 0.010 |
Why?
|
| Diabetic Nephropathies | 1 | 1992 | 19 | 0.010 |
Why?
|
| Triglycerides | 1 | 1992 | 117 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 1992 | 47 | 0.010 |
Why?
|
| Cholesterol | 1 | 1992 | 182 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1992 | 351 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1992 | 300 | 0.010 |
Why?
|
| Incidence | 1 | 1992 | 545 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 1992 | 980 | 0.010 |
Why?
|
| Time Factors | 1 | 1992 | 1562 | 0.000 |
Why?
|